Home » Newsletters » BioWorld Science

BioWorld Science

April 14, 2005

View Archived Issues

5-HT1A receptor stimulation reduces damage after cerebral infarction

GSK-3beta: a therapeutic target for pancreatic cancer

NeuGene antisense technology validation for dengue fever and West Nile virus

West Nile virus recombinant DNA plasmid vaccine moves into phase I studies / News in Context

Phase III PolyHeme study cleared to continue

DiObex licenses rights to cortisol inhibitors from Cortendo

Trigen and ProCorde merge

Reminyl renamed Razadyne

Approval for Femara in Canada

Perlegen licenses PPAR agonist from Mitsubishi Pharma

GCAN-101 under evaluation in phase II study

European phase II study of SPI-153 for hormone-dependent prostate cancer

Approvable letter for Ambien CR

Ferring launches Menopur

AM-Pharma receives subsidy for development of hLF1-11

FDA requests boxed warnings on atypical antipsychotics

GTI-2040 combination therapy completes phase II trial in kidney cancer

Ocaperidone reported effective in schizophrenia

New data on the antiepileptic efficacy of lacosamide

Sodium valproate reported to induce no changes in the PK profile of talampanel

Low dopamine receptor availability found in patients with mTLE

Pharmexa to acquire GemVax

New treatments claimed for allergic reactions and respiratory diseases

New class of inhibitors of HBsAg secretion described

New treatment for hot flushes in prostate cancer patients claimed by Boehringer Ingelheim

Naphthalene derivative identified as HIV-1 inhibitor

New sodium channel blockers emerge from Ionix R&D

Farnesyltransferase inhibitors tipifarnib, BMS-214662 evaluated in phase I studies

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...